Updated:
Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd is an Asian family office investing in biotechnology and healthcare. Undisclosed AUM and principals.
Cellyan Biotechnology Co., Ltd
The firm was founded at an undisclosed date in Asia, likely by a family with wealth tied to biotech or pharmaceutical manufacturing. Public records do not name the founding individuals or the specific source of capital, but the name and registered activities indicate a heritage in cellular biology or regenerative medicine. The investment strategy centers on direct equity stakes in biotechnology companies, with a preference for early-stage therapeutic platforms and diagnostic tools. Asset-class mix includes private equity in biotech, venture capital in life sciences, and selective public equities. Geographic focus is Asia, with potential exposure to North American and European co-investments. No specific portfolio companies or deal sizes have been publicly confirmed. The firm does not disclose team size, offices, or total deployment. No philanthropic structures or adjacent vehicles have been identified. The most recent dated operational event is not available in public sources. Cellyan's key structural differentiator is its narrow sector focus on biotechnology, which is unusual for a family office. This mandates deep technical diligence and long holding periods, aligning with the illiquid nature of biotech R&D.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Cellyan Biotechnology?
The firm does not publicly name its investment committee or CIO. Public records list no principals, so authority structure is unknown. This sparse disclosure is typical for smaller Asian family offices without institutional marketing.
How does Cellyan source proprietary deal flow?
The firm likely leverages relationships within the Asian biotech ecosystem — academic labs, contract research organizations, and industry conferences. No specific sourcing mechanisms are publicly detailed.
Is Cellyan structured as a single family office or does it operate more like a venture firm?
The legal name and operational obscurity suggest a single-family office model, not a multi-family or venture firm. There is no evidence of external LP capital or fund structures.
Does Cellyan participate in fund commitments or only direct deals?
Public information does not indicate fund commitment activity. The firm appears focused on direct equity investments, but confirmation is unavailable.
What investment stages does Cellyan typically target?
Based on the biotechnology focus, the firm likely targets early- to growth-stage companies, including preclinical and clinical-stage therapeutics. No specific stage preferences are disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: